Tunstall And Honeywell HomMed Join Forces To Advance Telemedicine Market
Added: (Tue Oct 04 2005)
Pressbox (Press Release) -
Tunstall to add market-leading Honeywell HomMed monitor to its
04 October, 2005 – Tunstall, the leader in telecare and telehealth solutions, has announced a distribution and alliance agreement with Honeywell HomMed, the leading provider of remote patient monitoring devices in the United States.
Tunstall will be offering Honeywell’s HomMed Genesis monitor throughout the United Kingdom. The emphasis will be on chronic disease management, in line with the Department of Health’s key initiative on the new long-term conditions National Service Framework.
The Genesis monitor is provided to patients at home by healthcare professionals to deliver more proactive and preventative levels of care for conditions such as COPD, diabetes and congestive heart failure. The monitor allows patients to measure their own weight, heart rate, blood oxygen levels, blood pressure and glucose levels. It can also ask a range of clinical and educational questions in one of 11 languages that primarily aim to further determine a patient’s condition. As a result, if patients with chronic conditions experience a change in their health status, proactive medical intervention can take place.
“We are delighted to work with Honeywell HomMed and be able to offer Genesis as part of our telecare and telemedicine portfolio,” said James Buckley, Tunstall’s Chief Executive Officer. “This alliance will help us to deliver more proactive models of care for the management of chronic diseases as part of the Government’s National Service Framework.”
To date, more than 350,000 patients have benefited from Honeywell HomMed remote patient monitors and there are already 300 clinical sites utilising the Genesis monitor in the US. A study by an independent health data services company reported that when Honeywell HomMed monitors were linked with integrated medical management plans, hospitalisations and emergency care visits were reduced significantly.
“This alliance will now give us valuable means of introducing the Honeywell HomMed remote monitoring solution into the European market,” said Herschel Peddicord, Honeywell HomMed’s President and Chief Executive Officer.
For more information about telemedicine technology, visit www.tunstallgroup.com.
Established in the UK in 1957, Tunstall is the world leading manufacturer and provider of personal and home reassurance telecare solutions, which help an increasing range of people at risk in their own homes or at work. Tunstall solutions are developed and delivered in partnership with a wide range of client organisations, including local authority housing and social services departments, housing associations, care providers in the public and private sector, NHS and private health care providers, police, schools, retirement property developers and charities and voluntary groups. Tunstall designs, manufactures, supplies and installs solutions and provides after-sales service to its partners throughout the United Kingdom.
About Honeywell HomMed:
Honeywell HomMed is a leader in the medical device industry and concentrates all of its expertise on telemonitoring. Honeywell HomMed’s product line includes two models of telemonitors as well as Central Station software – all are FDA Class II medical devices (hospital grade). Honeywell HomMed, currently, has more patients actively using its telemonitoring equipment in their homes than all other providers of home telemonitoring combined. Honeywell HomMed is a part of Honeywell International, a $26 billion diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell’s shares are traded on the New York, London, Chicago and Pacific Stock Exchanges. It is one of the 30 stocks that make up the Dow Jones Industrial Average and is also a component of the Standard & Poor's 500 Index. For additional information, please visit www.hommed.com or www.honeywell.com.